Methods: A target-based Mendelian randomization was performed to appraise whether inhibiting the IL-6 signaling pathway via IL-6R blockade can reduce the risk of NAFLD. The gene discussed is IL6; the disease is metabolic dysfunction-associated steatotic liver disease.